Article Text

PDF

Trial registration, the ICMJE statement, and paediatric journals
  1. M Bonati,
  2. C Pandolfini
  1. “Mario Negri” Pharmacological Research Institute, Milan, Italy
  1. Correspondence to:
    Dr M Bonati
    Laboratory for Mother and Child Health, Istituto di Ricerche Farmacologiche “Mario Negri”, Via Eritrea 62, 20157 Milano, Italy; mother_child{at}marionegri.it

Statistics from Altmetric.com

The risk of wide unnecessary duplication (as opposed to necessary replication) in research, including paediatric research,1 is high. Furthermore, the risk of research findings disappearing from the public knowledge base is especially high for negative trials. Prospective registration of clinical trials should reduce such inadequacies, promote collaboration, facilitate disclosure of information to the public and those involved in health care, and reduce waste of effort and resources.2

The issue has been widely debated in the biomedical journals and many groups have begun to discuss their role in such a matter. In September 2004, the International Committee of Medical Journal Editors (ICMJE), representing 11 different medical journals (plus the British Medical Journal which also joined the initiative), published a statement specifying their intent to require, as a condition of consideration for publication, registration of trials in a public trials registry at onset of patient enrolment.3 Trials starting recruitment after 1 July 2005 will now be considered for publication in the 12 journals only if they have registered by that date. Trials beginning enrolment before then must have registered by 13 September.

It is important that all knowledge gained from trials concerning populations with an evident lack of evidence based knowledge, such as children (who are at a disadvantage compared to adults with respect to optimal drug therapy), be made publicly available. Trial registration should contribute to closing the gap. Patients (and their parents) who volunteer to participate in trials deserve to know that their contributions will inform future healthcare decisions.

In such a context, although the issue for paediatrics was settled without success 15 years ago,4 we would like to point out that none of the journals that have participated in the discussion on trial registration are paediatric journals. We feel it is fundamental that children be kept well in mind when discussing such an issue and feel that paediatric journals should therefore participate actively in the matter.

A European register of clinical trials on drug therapy in children (www.dec-net.org) has been running since mid 2004, supported by the European Union under its Fifth Framework Programme, Thematic Programme “Quality of Life” (contract QLG4-CT-2002-01054). At present, DEC-net (in addition to www.clinicaltrials.gov, the US National Library of Medicine’s register) is the only one fitting the ICMJE’s criteria, which state that a register must be freely accessible to the public; open to all prospective registrants; managed by a non-profit organisation; electronically searchable; contain validated data, and include a set of minimal data (a unique ID number, the study interventions, hypothesis, primary and secondary outcome measures, eligibility criteria, key trial dates, target number of subjects, funding source, and contact information for the principal investigator).

Trial registration has become a public issue: the World Health Organisation supports initiatives devoted to disclosing standard information5 on ongoing clinical trials, and governments around the world are beginning to make trial disclosure mandatory.

We would like to ask paediatric journals to make their positions on trial registration known and would like to reiterate the important role that a register such as DEC-net can have in the matter.

References

View Abstract

Footnotes

  • Competing interests: none declared

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.